D
Dave Demets
Researcher at University of Wisconsin-Madison
Publications - 3
Citations - 68
Dave Demets is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Clinical and Translational Science Award & MEDLINE. The author has an hindex of 2, co-authored 3 publications receiving 43 citations.
Papers
More filters
Journal ArticleDOI
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Abhinav Sharma,Abhinav Sharma,Neha J. Pagidipati,Robert M. Califf,Darren K. McGuire,Jennifer B. Green,Dave Demets,Jyothis T. George,Hertzel C. Gerstein,Todd Hobbs,Rury R. Holman,Francesca C. Lawson,Lawrence A. Leiter,Marc A. Pfeffer,Jane E.B. Reusch,Jeffrey S. Riesmeyer,Matthew T. Roe,Yves Rosenberg,Robert Temple,Stephen D. Wiviott,John J.V. McMurray,Christopher B. Granger +21 more
TL;DR: Recommendations include requiring only the 1.3 noninferiority margin for regulatory approval, conducting trials for longer durations, considering studying glucose-lowering therapies as first-line management of type 2 diabetes mellitus, and considering heart failure or kidney outcomes within the primary outcome.
Journal ArticleDOI
Evaluation metrics for biostatistical and epidemiological collaborations.
Doris M. Rubio,Deborah J. del Junco,Rafia Bhore,Christopher J. Lindsell,Robert A. Oster,Knut M. Wittkowski,Leah J. Welty,Yi-Ju Li,Dave Demets +8 more
TL;DR: The routine application, comparison of findings across diverse BERD units, and ongoing refinement of the metrics will identify trends, facilitate meaningful changes, and ultimately enhance the contribution of B ERD activities to biomedical research.
Journal ArticleDOI
The end of the beginning: A commentary on ‘Evaluation metrics for biostatistical and epidemiological collaborations’: A rejoinder
Doris M. Rubio,Deborah J. del Junco,Rafia Bhore,Christopher J. Lindsell,Robert A. Oster,Knut M. Wittkowski,Leah J. Welty,Yi-Ju Li,Dave Demets +8 more
TL;DR: Three aspects of the next phase of evaluation of biostatistical and epidemiological collaborations are highlighted, including the importance of the work may be realized only through implementation of the framework and the utility and meaning of the measurements have yet to be tested.